Oral Presentation

[29-412-pm] Antibacterial, antiviral and antifungal agents 2/Vaccines and bioactive agents

Fri. Mar 29, 2024 4:30 PM - 5:42 PM [Room 412] Conference Center 412 (4F)

Chair: Yuuki Shiiba, Hiroshi Mizuuchi

+Add all to schedule

4:30 PM - 4:42 PM

[29-412-pm16] Studies on evaluation of isoflavone against human coronavirus

○Haruna Matsubayashi¹, Shogo Kameda¹, Masayo Ogawa¹, Miki Umeda², Masaya Takemoto¹, Tohru Daikoku¹ (1. Pharm. Sci., Hokuriku Univ., 2. Grad. Sch. Med., Nagoya Univ.)

4:42 PM - 4:54 PM

[29-412-pm17] Identification of broad neutralizing antibody against SARS-CoV-2 variants including EG.5.1.

○HANAKO ISHIMARU¹, Mitsuhiro Nishimura¹, Hideki Shigematsu², Maria Istiqomah Marini¹, Natsumi Hasegawa¹, Rei Takamiya¹, Sachiyo Iwata³, Yasuko Mori¹ (1. Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, 2. Structural Biology Division, Japan Synchrotron Radiation Research Institute SPring-8, 3. Division of Cardiovascular Medicine, Hyogo Prefectural Kakogawa Medical Center)

4:54 PM - 5:06 PM

[29-412-pm18] Development of live attenuated SARS-CoV-2 vaccine with combined substitutions and deletions responsible to attenuation

○Mie Suzuki¹, Shinya Okamura^1,2, Akiho Yoshida^1,2, Gis Tang¹, Yuka Koizumi¹, Mai Matsumoto¹, Suni Lee¹, Shiro Takekawa¹, Koichi Yamanishi¹, Hirotaka Ebina^1,2,3 (1. The research foundation for microbial diseases of osaka university, 2. Virus Vaccine group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, 3. The Research Institute for Microbial Diseases of Osaka University)

5:06 PM - 5:18 PM

[29-412-pm19S] Development of Vero cell-adapted enterovirus D68 strains for vaccine production

○Kota Senpuku^1,2, Chikako Nakamura³, Yuta Kunishima^2,3, Kotaro Taniguchi^1,2, Toshiro Hirai^1,2,4,5, Yasuo Yoshioka^{1,2,3,4,5,6,7} (1. Grad. Sch. Pharm. Sci., Osaka Univ., 2. RIMD, Osaka Univ., 3. BIKEN, 4. OTRI, Osaka Univ., 5. CAMaD, Osaka Univ., 6. MEI, Osaka Univ., 7. CiDER, Osaka Univ.)

5:18 PM - 5:30 PM

[29-412-pm20] Development of mRNA vaccine against enterovirus D68

○Yuta Kunishima^1,2, Kota Senpuku^2,3, Chikako Nakamura¹, Yasuo Yoshioka^{1,2,3,4,5,6,7} (1. BIKEN, 2. RIMD, Osaka Univ., 3. Grad. Sch. Pharm. Sci., Osaka Univ., 4. OTRI, Osaka Univ, 5. CAMaD, Osaka Univ., 6. MEI, Osaka Univ., 7. CiDER, Osaka Univ.)

5:30 PM - 5:42 PM

[29-412-pm21S] Evaluation of the vaccine potential of replication-incompetent Ebola virus

○Sara Yoshimoto¹, Makoto Kuroda², Shintaro Shichinohe¹, Itsuki Anzai^1,3, Kosuke Takada¹, Ayato Takada⁴, Peter Halfmann², Yoshihiro Kawaoka^2,5,6,7, Tokiko Watanabe^1,3,8 (1. RIMD, Osaka Univ., 2. Influenza Research Institute, University of Wisconsin-Madison, 3. CiDER, Osaka Univ., 4. IIZC, Hokkaido Univ., 5. IMSUT, Tokyo Univ., 6. NCGM, 7. UTOPIA, Tokyo Univ., 8. CAMad)

Session information